The effect of peripheral vasopressor protocols on extravasation rates: A systematic review and meta-analysis.

J Crit CareMay 17, 2026 (epub)
Clinical ResearchEmergency MedicineAnesthesiology

Jessica F Wiseman, Vanessa H Wiseman, Natasha A Jawa et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of peripheral vasopressor protocols on extravasation rates in critically ill patients. Analyzing 22 studies with 10,983 adult patients, the results showed no significant difference in extravasation rates between protocols and non-protocols, with rates of 33.5 vs 31.2 per 1000 patients, respectively (p = 0.78).

Key findings

  • Median extravasation rates were 33.5 per 1000 patients for protocols and 31.2 for non-protocols.
  • No statistically significant difference in extravasation rates was found (p = 0.78).
  • The review included 22 studies with a total of 10,983 adult patients.

Why it matters

Understanding the safety profile of peripheral vasopressor administration is crucial for clinicians managing critically ill patients, especially as peripheral access may reduce procedural risks associated with central venous catheters.

Source

PubMed · PMID 42143789

Published in J Crit Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Emergency Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.